BioArctic AB (BRCTF) reports significant licensing deals and growing market demand, while navigating regulatory challenges and increased expenses.

Scientists explore how the immune and nervous systems constantly communicate, influencing brain diseases, behavior, and ...

Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

The Brigham and Women's Hospital Inc., Massachusetts General Hospital and UCL Business Ltd. have jointly patented new benzo[c][l,2,5]thiadiazolyl compounds and radiolabeled derivatives targeting ...

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...

Parkinson’s disease is a brain disorder that affects movement, making everyday tasks difficult for nearly one million people ...

It’s been a minute since Lifehacker looked at the slang of Generation Z—long enough that Generation Alpha has had time to develop and spread some of its own special buzzwords and jargon.

“In that illness, there’s a different type of protein called alpha-synuclein, which is deposited. But there are now antibody trials mopping up the alpha-synuclein to see if it changes progression in ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...